Cognitive Outcomes in Children No Better With Levothyroxine Tx

Share this content:
Cognitive Outcomes in Children No Better With Levothyroxine Tx
Cognitive Outcomes in Children No Better With Levothyroxine Tx

THURSDAY, March 2, 2017 (HealthDay News) -- Treatment for subclinical hypothyroidism or hypothyroxinemia before 20 weeks of gestation is not associated with better cognitive outcomes in children, according to a study published in the March 2 issue of the New England Journal of Medicine.

Brian M. Casey, M.D., from the University of Texas Southwestern Medical Center in Dallas, and colleagues screened women with a singleton pregnancy for subclinical hypothyroidism and for hypothyroxinemia before 20 weeks of gestation. Women were randomized to levothyroxine or placebo in separate trials: 677 women with subclinical hypothyroidism underwent randomization at a mean of 16.7 weeks of gestation and 526 with hypothyroxinemia were randomized at a mean of 17.8 weeks of gestation.

The researchers found that the median IQ score of children at age 5 years was 97 and 94 in the levothyroxine and placebo groups, respectively, in the subclinical hypothyroidism trial (P = 0.71), and 94 and 91, respectively, in the hypothyroxinemia trial (P = 0.30). IQ scores were missing for 4 percent of children in each trial. No significant between-group differences were seen in either trial for any neurocognitive or pregnancy outcomes or for adverse event incidence.

"Treatment for subclinical hypothyroidism or hypothyroxinemia beginning between 8 and 20 weeks of gestation did not result in significantly better cognitive outcomes in children through 5 years of age than no treatment for those conditions," the authors write.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »